Penn study finds low uptake of first mutation-targeted bladd

The first bladder cancer drug targeting a cancer-driving gene mutation has been used relatively little despite its clear efficacy in a clinical trial, suggests a study from researchers at the Perelman School of Medicine at the University of Pennsylvania.

Related Keywords

United States , Americans , American , Vivek Nimgaonkar , Ronac Mamtani , Emily Henderson , Penn Center , University Of Pennsylvania , Drug Administration , Biopsy Laboratory , Perelman School Of Medicine , American Cancer Society , Perelman School , Erica Carpenter , Liquid Biopsy , Fibroblast Growth Factor Receptors , Bladder , Bladder Cancer , Dancer , Utation , Biopsy , Cancer Treatment , Carcinomas , Chemotherapy , Clinical Trial , Education , Efficacy , Gene , Enetic , Hospital , Medicine , Ncology , Precision Medicine , Research , Humor ,